<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="joa370093" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Arrhythm</journal-id><journal-id journal-id-type="iso-abbrev">J Arrhythm</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1883-2148</journal-id><journal-id journal-id-type="publisher-id">JOA3</journal-id><journal-title-group><journal-title>Journal of Arrhythmia</journal-title></journal-title-group><issn pub-type="ppub">1880-4276</issn><issn pub-type="epub">1883-2148</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40390786</article-id><article-id pub-id-type="pmc">PMC12086514</article-id>
<article-id pub-id-type="doi">10.1002/joa3.70093</article-id><article-id pub-id-type="publisher-id">JOA370093</article-id><article-id pub-id-type="other">JOA-2025-0071.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prognostic comparison between implantable cardioverter&#x02010;defibrillator and amiodarone in cancer patients</article-title><alt-title alt-title-type="left-running-head">Kida et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="joa370093-cr-0001" contrib-type="author" corresp="yes"><name><surname>Kida</surname><given-names>Hirota</given-names></name><degrees>CE, MS, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3718-554X</contrib-id><xref rid="joa370093-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>kidahirotaogmce@gmail.com</email></address></contrib><contrib id="joa370093-cr-0002" contrib-type="author"><name><surname>Morishima</surname><given-names>Toshitaka</given-names></name><degrees>MD, PhD</degrees><xref rid="joa370093-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="joa370093-cr-0003" contrib-type="author"><name><surname>Uza</surname><given-names>Eiji</given-names></name><degrees>CE, MS</degrees><xref rid="joa370093-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="joa370093-cr-0004" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Hironori</given-names></name><degrees>MD, PhD</degrees><xref rid="joa370093-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="joa370093-cr-0005" contrib-type="author"><name><surname>Yasui</surname><given-names>Taku</given-names></name><degrees>MD, PhD</degrees><xref rid="joa370093-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="joa370093-cr-0006" contrib-type="author"><name><surname>Fujita</surname><given-names>Masashi</given-names></name><degrees>MD, PhD</degrees><xref rid="joa370093-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="joa370093-cr-0007" contrib-type="author"><name><surname>Miyashiro</surname><given-names>Isao</given-names></name><degrees>MD, PhD</degrees><xref rid="joa370093-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="joa370093-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Engineering</named-content>
<institution>Osaka International Cancer Institute</institution>
<city>Osaka</city>
<country country="JP">Japan</country>
</aff><aff id="joa370093-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Cancer Control Center</named-content>
<institution>Osaka International Cancer Institute</institution>
<city>Osaka</city>
<country country="JP">Japan</country>
</aff><aff id="joa370093-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Onco&#x02010;Cardiology</named-content>
<institution>Osaka International Cancer Institute</institution>
<city>Osaka</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Hirota Kida, Department of Clinical engineering, Osaka International Cancer Institute, 3&#x02010;1&#x02010;69 Otemae, Chuou&#x02010;ku, Osaka 540&#x02010;0008, Japan.<break/>
Email: <email>kidahirotaogmce@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>41</volume><issue seq="479">3</issue><issue-id pub-id-type="doi">10.1002/joa3.v41.3</issue-id><elocation-id>e70093</elocation-id><history>
<date date-type="rev-recd"><day>26</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>03</day><month>2</month><year>2025</year></date>
<date date-type="accepted"><day>04</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Japanese Heart Rhythm Society.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Arrhythmia</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JOA3-41-e70093.pdf"/><abstract><title>Abstract</title><sec id="joa370093-sec-0001"><title>Background</title><p>Implantable cardioverter&#x02010;defibrillator (ICD) has been demonstrated to improve survival outcomes compared to amiodarone. However, this effectiveness in cancer patients remains unclear. Given the complexity of cardiovascular management in this population, including cancer stage considerations, we evaluated the relative effectiveness of ICD versus amiodarone in cancer patients.</p></sec><sec id="joa370093-sec-0002"><title>Methods and Results</title><p>We linked cancer registry data with administrative records to identify patients newly prescribed amiodarone or who underwent ICD implantation between 2010 and 2015 at 36 hospitals in Osaka Prefecture, Japan. Among 161,125 cancer patients, 339 met the inclusion criteria (amiodarone: <italic toggle="no">n</italic>&#x02009;=&#x02009;281; ICD: <italic toggle="no">n</italic>&#x02009;=&#x02009;58), with a median follow&#x02010;up of 762&#x02009;days. Kaplan&#x02013;Meier analysis revealed that the ICD group had a significantly reduced risk of all&#x02010;cause mortality compared to the Amiodarone group (Log&#x02010;rank test, <italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;.003). Multivariable Cox proportional hazard regression model showed that ICD was an independent prognostic factor (Hazard ratio: 0.47, 95% confidence interval: 0.29&#x02013;0.79, <italic toggle="no">p</italic>&#x02009;=&#x02009;.004). These results were confirmed in a propensity&#x02010;matched analysis. Among patients with cancer stage: in&#x000a0;situ or localized, no significant difference in survival risk was observed between the ICD and Amiodarone groups, and ICD was not significantly associated with all&#x02010;cause death. Conversely, among patients with cancer stage: regional or distant, the ICD group had a significantly reduced risk of all&#x02010;cause death compared to the Amiodarone group, and ICD was an independent prognostic factor.</p></sec><sec id="joa370093-sec-0003"><title>Conclusion</title><p>In cancer patients, ICD may improve long&#x02010;term prognosis compared to amiodarone, especially in patients with advanced cancer stages.</p></sec></abstract><abstract abstract-type="graphical"><p>The effectiveness of implantable cardioverter&#x02010;defibrillator (ICD) versus amiodarone in cancer patients remains unclear. Using 2010&#x02013;2015 cancer registry data from 36 hospitals in Osaka, Japan, we found that ICD significantly improves cancer patients' prognosis compared to amiodarone.<boxed-text position="anchor" content-type="graphic" id="joa370093-blkfxd-0001"><graphic xlink:href="JOA3-41-e70093-g003.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="joa370093-kwd-0001">amiodarone</kwd><kwd id="joa370093-kwd-0002">cancer</kwd><kwd id="joa370093-kwd-0003">implantable cardioverter defibrillator</kwd></kwd-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="9"/><word-count count="5700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:22.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="JOA370093-cit-2001">
<string-name>
<surname>Kida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Uza</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yasui</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Prognostic comparison between implantable cardioverter&#x02010;defibrillator and amiodarone in cancer patients</article-title>. <source>J Arrhythmia</source>. <year>2025</year>;<volume>41</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/joa3.70093</pub-id>
</mixed-citation>
</p></notes></front><body id="joa370093-body-0001"><sec id="joa370093-sec-0004"><label>1</label><title>INTRODUCTION</title><p>Cancer constitutes a substantial proportion of global mortality,<xref rid="joa370093-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> with projections indicating that over 28 million individuals will be living with cancer by 2040, representing a 47% rise compared to the 19.3 million cases reported in 2020.<xref rid="joa370093-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> On the other hand, cancer mortality is declining<xref rid="joa370093-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> and the long&#x02010;term survival rates among cancer patients have improved significantly on a global scale.<xref rid="joa370093-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="joa370093-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Cancer patients face a heightened risk of developing cardiovascular disease (CVD), as both diseases share overlapping risk factors such as hypertension, diabetes, and smoking.<xref rid="joa370093-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> These comorbidities commonly coexist, and CVD remains the primary cause of noncancer&#x02010;related mortality among cancer patients.<xref rid="joa370093-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>Implantable cardioverter&#x02010;defibrillator (ICD) is widely recognized as a highly effective treatment for the prevention of sudden cardiac death, supported by the evidence highlighting significant long&#x02010;term survival advantages in patients with the risk of ventricular arrhythmias.<xref rid="joa370093-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="joa370093-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Additionally, ICD is demonstrated to substantially improve survival outcomes compared to amiodarone.<xref rid="joa370093-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Conversely, cancer patients who underwent ICD implantation exhibit a poorer prognosis than their noncancer counterparts.<xref rid="joa370093-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Cardiovascular management for this population needs careful consideration of various factors, including the stage of cancer. Furthermore, the effectiveness of ICD compared to amiodarone in cancer patients remains unclear. In our study, we evaluated the relative effectiveness of ICD over amiodarone in cancer patients.</p></sec><sec sec-type="methods" id="joa370093-sec-0005"><label>2</label><title>METHODS</title><sec id="joa370093-sec-0006"><label>2.1</label><title>Data sources</title><p>In this study, we integrated two distinct data sources to create a comprehensive and unified database for analyzing the association between patient mortality and clinical parameters, such as ICD implantation and the use of amiodarone, which are not typically recorded in cancer registries.<xref rid="joa370093-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="joa370093-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="joa370093-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="joa370093-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Data were retrieved from patients diagnosed with cancer between 2010 and 2015 for analysis. The primary data source was the Osaka Cancer Registry (OCR), a population&#x02010;based registry that systematically gathers detailed information on cancer diagnoses and outcomes for residents of Osaka Prefecture, Japan. OCR data include patient characteristics such as gender, age at cancer diagnosis, vital status, dates of death or the last follow&#x02010;up, cancer site, and cancer stage. The cancer stage were classified as in&#x000a0;situ, localized, regional, distant, or unknown at diagnosis based on Surveillance, Epidemiology, and End Results (SEER).<xref rid="joa370093-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> The definition of in&#x000a0;situ stage is the presence of malignant cells within the cell group from which they arose with no penetration of the basement membrane of the tissue and no stromal invasion. The definition of localized stage is a malignancy limited to the organ of origin, which spread no farther. The definition of regional stage is tumor extension beyond the limits of the organ of origin. The definition of distant stage is that tumor cells that have broken away from the primary tumor, have traveled to other parts of the body, and have begun to grow at the new location. Vital status follow&#x02010;up was routinely conducted using death certificates. Additionally, in May 2019, official resident registries were employed to verify and update the vital status of patients.</p><p>The second data source comprised administrative records derived from Japan's Diagnosis Procedure Combination (DPC) Per&#x02010;Diem Payment System, which regulates insurer reimbursements to acute care hospitals. DPC data are among the most widely used hospital administrative datasets for research in Japan.<xref rid="joa370093-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> These records provide clinical summaries and detailed insurance claims, including information on comorbidities, New York Heart Association (NYHA) classification, medications, and ICD implantation. In collaboration with the Council for Coordination of Designated Cancer Care Hospitals in Osaka, we obtained DPC data from hospitals affiliated with the OCR. The two datasets were merged at the patient level using each hospital's unique patient identification number as the linkage key.</p></sec><sec id="joa370093-sec-0007"><label>2.2</label><title>Study population</title><p>We identified cancer from OCR regardless of the location. Cancers were grouped into the following 16 categories: mouth/pharynx (topographical codes: C00&#x02013;14), esophagus (C15), stomach (C16), colorectal (C18&#x02013;20), liver (C22), gallbladder and bile duct (C23&#x02013;24), pancreas (C25), lung (C33&#x02013;34), skin (C44), breast (C50), cervix uteri (C53), prostate (C61), kidney (C64), bladder (C67), urinary tract (C68), and other cancers (all other Cxx codes) based on the International Classification of Diseases for Oncology Third Edition (ICD&#x02010;O&#x02010;3). In instances of simultaneous multiple cancer diagnoses, the malignancy with the most advanced stage was designated as the primary cancer. We identified patients who were newly prescribed amiodarone or who underwent ICD implantation, including those receiving cardiac resynchronization therapy defibrillator (CRT&#x02010;D), following a cancer diagnosis between January 1, 2010 and December 31, 2015 from linked data. Patients who had prescribed amiodarone or who had undergone ICD implantation prior to their cancer diagnosis were excluded.</p></sec><sec id="joa370093-sec-0008"><label>2.3</label><title>Comorbidities and medications</title><p>The structure of DPC data enables hospitals to document the presence of comorbidities for each patient. All comorbidities were extracted from the relevant data fields in the DPC file corresponding to the most recent hospitalization where amiodarone was prescribed or an ICD (include CRT&#x02010;D) was implanted. Comorbidities are documented utilizing the International Classification of Diseases, Tenth Revision (ICD&#x02010;10) codes. To identify a history of diabetes, chronic heart failure, chronic kidney disease, prior myocardial infarction, cardiomyopathy, and ventricular tachycardia/ventricular fibrillation (VT/VF), we classified the disease recorded on the DPC in accordance with QUAN's report<xref rid="joa370093-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and the guidelines of the Japanese Circulation Society.<xref rid="joa370093-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="joa370093-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The details of these classifications are shown in Table&#x000a0;<xref rid="joa370093-supitem-0001" ref-type="supplementary-material">S1</xref>. Data on medications such as beta&#x02010;blockers, angiotensin&#x02010;converting enzyme inhibitors (ACEs), angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) were extracted from the DPC database.</p></sec><sec id="joa370093-sec-0009"><label>2.4</label><title>Endpoint</title><p>The primary endpoint of this study was all&#x02010;cause mortality. The outcomes were evaluated at 5&#x02009;years after newly prescribed amiodarone or an ICD (include CRT&#x02010;D) was implanted. This study was approved by the local ethics committee of Osaka International Cancer Institute, which approved the study protocol (Approval number: 1707105108). Informed consent was not required, as the study was retrospective in nature, and the committee allowed for the opt&#x02010;out approach for the secondary use of existing data.</p></sec><sec id="joa370093-sec-0010"><label>2.5</label><title>Statistical analysis</title><p>Categorical variables were presented as number (frequency) and compared using the chi&#x02010;squared test or Fisher's exact test between 2 groups, amiodarone group and ICD group. Continuous variables were presented as medians (interquartile) and compared using Mann&#x02013;Whitney U test between 2 groups. Days of survival were analyzed with Kaplan&#x02013;Meier curves and differences were tested using the log&#x02010;rank test between 2 groups. Multivariable COX proportional hazard model was used to assess the effect of ICD adjusted for the following clinically relevant covariates selected based on clinical consensus: age, gender, diabetes, chronic kidney disease, prior myocardial infarction, cardiomyopathy, NYHA class II or more, VT/VF, cancer stage: in&#x000a0;situ or localized, interval from diagnosis of cancer to treatment, and medications such as &#x003b2;&#x02010;blockers, ACEs, ARBs, and MRAs.</p><p>Then, we divided patients into two groups based on the cancer stage: in&#x000a0;situ or localized, and regional or distant. In each group, days of survival were analyzed with Kaplan&#x02013;Meier curves and differences were tested using the log&#x02010;rank test. A multivariable COX proportional hazard model was used to assess the effect of ICD adjusted for the following clinically relevant covariates: age, gender, diabetes, chronic kidney disease, prior myocardial infarction, cardiomyopathy, VT/VF, and interval from diagnosis of cancer to treatment.</p><p>As a sensitivity analysis, we further evaluated the association between ICD implantation and prognosis within a propensity score&#x02010;matched cohort comprising patients who newly prescribed amiodarone or underwent ICD implantation. The propensity score for each patient was calculated using logistic regression incorporating the following parameters: age, gender, cancer stage: in&#x000a0;situ or localized, cancer stage: regional, cancer stage: distant, interval from diagnosis of cancer to treatment, cardiomyopathy, VT/VF, mainly focusing on variables related to cancer. Using propensity scores, 1:1 nearest&#x02010;neighbor matching was conducted with a caliper width set at 0.20 times the standard deviation of the propensity score to match these patients. The matching process was implemented using the function Match from the &#x0201c;Matching&#x0201d; package in R. The proportional hazards assumption for ICD related to the primary endpoint was validated through the analysis of Schoenfeld residuals (<italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;.05). All analyses were performed using R software (version 4.0.0; R Foundation for Statistical Computing, Vienna, Austria) with R Studio (version 3,6,1; Boston, MA, USA), and two&#x02010;tailed <italic toggle="yes">p</italic> values &#x0003c;.05 were considered indicative of statistical significance.</p></sec></sec><sec sec-type="results" id="joa370093-sec-0011"><label>3</label><title>RESULTS</title><sec id="joa370093-sec-0012"><label>3.1</label><title>Baseline characteristics</title><p>From a large consolidated database (<italic toggle="yes">N</italic>&#x02009;=&#x02009;161.125), we identified 339 patients who were newly prescribed amiodarone (<italic toggle="yes">N</italic>&#x02009;=&#x02009;281) or underwent ICD implantation (<italic toggle="yes">N</italic>&#x02009;=&#x02009;58) (Figure&#x000a0;<xref rid="joa370093-fig-0001" ref-type="fig">1</xref>). Baseline clinical characteristics are shown in Table&#x000a0;<xref rid="joa370093-tbl-0001" ref-type="table">1</xref>. The ICD group included 38 of the 58 patients (65.5%) who underwent CRT&#x02010;D as well as ICD. The majority of patients in both the Amiodarone and ICD groups were predominantly at cancer stages: in&#x000a0;situ or localized (the Amiodarone group: 59.8%, the ICD group: 63.8%). In both groups, the predominant sites of cancer occurrence, ranked in descending order, were the colon (the Amiodarone group: 19.9%, the ICD group: 20.7%), stomach (the Amiodarone group: 12.5%, the ICD group: 19.0%), lung (the Amiodarone group: 10.0%, the ICD group: 5.2%), and liver (the Amiodarone group: 7.5%, the ICD group: 5.2%). Compared to the Amiodarone group, the ICD group significantly had a higher prevalence of cardiomyopathy, chronic heart failure, VT/VF, NYHA II or more, and drugs such as ACEs or ARBs, MRAs, &#x003b2;&#x02010;blockers, and a longer interval between cancer diagnosis and either ICD implantation or amiodarone prescription.</p><fig position="float" fig-type="FIGURE" id="joa370093-fig-0001"><label>FIGURE 1</label><caption><p>Study population. ICD, Implantable cardioverter&#x02010;defibrillator.</p></caption><graphic xlink:href="JOA3-41-e70093-g004" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="joa370093-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Amiodarone</th><th align="left" valign="bottom" rowspan="1" colspan="1">ICD</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Number</td><td align="left" valign="top" rowspan="1" colspan="1">281</td><td align="left" valign="top" rowspan="1" colspan="1">58</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient data</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age, (years)</td><td align="left" valign="top" rowspan="1" colspan="1">72 [66, 78]</td><td align="left" valign="top" rowspan="1" colspan="1">70 [63, 75]</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.084</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">216 (76.9)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (81.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.603</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CRT&#x02010;D, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">38 (65.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabetes, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">80 (28.5)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (41.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.074</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic kidney disease, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (21.4)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (22.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.997</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prior myocardial infarction</td><td align="left" valign="top" rowspan="1" colspan="1">44 (15.7)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (19.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.670</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic heart failure, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">159 (56.6)</td><td align="left" valign="top" rowspan="1" colspan="1">43 (74.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.020</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cardiomyopathy, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (27.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NYHA II or more, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (16.0)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (36.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">History of VT or VF, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (16.7)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (62.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancer</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Interval between cancer diagnosis and Amiodarone or ICD (days)</td><td align="left" valign="top" rowspan="1" colspan="1">298 [58, 955]</td><td align="left" valign="top" rowspan="1" colspan="1">592 [301, 1307]</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.004</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cancer stage: in&#x000a0;situ or localized, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">168 (59.8)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (63.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.674</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cancer stage: regional, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">52 (18.5)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (20.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.714</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cancer stage: distant, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (6.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.478</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Stomach, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (19.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.268</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Colon, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">56 (19.9)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (20.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lung, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (5.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.367</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liver, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (7.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (5.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.733</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medications</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ACE or ARB, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">180 (64.1)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (79.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.037</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MRA, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">132 (47.0)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (70.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.002</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x003b2;&#x02010;blocker, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">193 (68.7)</td><td align="left" valign="top" rowspan="1" colspan="1">53 (91.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.001</td></tr></tbody></table><table-wrap-foot id="joa370093-ntgp-0001"><fn id="joa370093-note-0001"><p>
<italic toggle="yes">Note</italic>: Data are expressed as median [interquartile range] or number (column percentage).</p></fn><fn id="joa370093-note-0002"><p>Abbreviations: ACE, angiotensin&#x02010;converting enzyme inhibitor; ARB, angiotensin II receptor blockers; CRT&#x02010;D, cardiac resynchronization therapy defibrillator; ICD, Implantable cardioverter&#x02010;defibrillator; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; VF, ventricular fibrillation; VT, ventricular tachycardia.</p></fn></table-wrap-foot></table-wrap></sec><sec id="joa370093-sec-0013"><label>3.2</label><title>Clinical endpoint</title><p>During a median follow&#x02010;up period of 762&#x02009;days, among a total 339 patients, 179 patients (52.8%) died within 5&#x02009;years after diagnosis of cancer. Kaplan&#x02013;Meier analysis revealed that the ICD group had a significantly reduced risk of all&#x02010;cause death than the Amiodaron group, with a 5&#x02010;year survival rate of 58.0% versus 33.4%, respectively (Log&#x02010;rank test, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;.003) (Figure&#x000a0;<xref rid="joa370093-fig-0002" ref-type="fig">2</xref>). Multivariable Cox proportional hazard regression model showed that ICD was an independent prognostic factor (Hazard ratio: 0.47, 95% confidence interval: 0.29&#x02013;0.79, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.004).</p><fig position="float" fig-type="FIGURE" id="joa370093-fig-0002"><label>FIGURE 2</label><caption><p>Kaplan&#x02013;Meier curves stratified for 5&#x02010;year all&#x02010;cause death. We used a multivariable Cox proportional hazard model to compare the impact of ICD with Amiodarone on long&#x02010;term all&#x02010;cause mortality (5&#x02009;years). Multivariable model: Adjusted for age, gender, diabetes, chronic kidney disease, prior myocardial infarction, cardiomyopathy, NYHA class II or more, VT/VF, cancer stage: In&#x000a0;situ or localized, interval from diagnosis of cancer to treatment, and medications such as &#x003b2;&#x02010;blockers, ACEs, ARBs, and MRAs. ACEs, angiotensin&#x02010;converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CI, confidence interval; HR, hazard ratio; ICD, Implantable cardioverter&#x02010;defibrillator; MRAs, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; VF, ventricular fibrillation; VT, ventricular tachycardia.</p></caption><graphic xlink:href="JOA3-41-e70093-g005" position="anchor" id="jats-graphic-5"/></fig><p>Among patients with cancer stage: in&#x000a0;situ or localized (<italic toggle="yes">N</italic>&#x02009;=&#x02009;205), there were 91 all&#x02010;cause deaths (44.4%) over a median follow&#x02010;up period of 867 [304, 1398] days. Kaplan&#x02013;Meier analysis indicated no significant difference in survival risk between the ICD and Amiodarone groups, with 5&#x02010;year survival rates of 60.7% and 40.4%, respectively (Log&#x02010;rank test, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.092). In the multivariable Cox proportional hazard regression model, ICD was not significantly associated with all&#x02010;cause death (Hazard ratio: 0.67, 95% confidence interval: 0.34&#x02013;1.32, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.252). (Figure&#x000a0;<xref rid="joa370093-fig-0003" ref-type="fig">3A</xref>). Conversely, among patients with cancer stage: regional or distant (<italic toggle="yes">N</italic>&#x02009;=&#x02009;134), there were 88 all&#x02010;cause deaths (65.7%) over a median follow&#x02010;up period of 563 [121, 1172] days. Kaplan&#x02013;Meier analysis revealed that the ICD group had a significantly reduced risk of all&#x02010;cause death compared to the Amiodarone group, with 5&#x02010;year survival rates of 53.6% and 23.2%, respectively (Log&#x02010;rank test, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.009). The multivariable Cox proportional hazard regression model showed that ICD was an independent prognostic factor (Hazard ratio: 0.40, 95% confidence interval: 0.19&#x02013;0.85, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.017). (Figure&#x000a0;<xref rid="joa370093-fig-0003" ref-type="fig">3B</xref>).</p><fig position="float" fig-type="FIGURE" id="joa370093-fig-0003"><label>FIGURE 3</label><caption><p>Kaplan&#x02013;Meier curves stratified by cancer stages (stage: In&#x000a0;situ or localized and stage: Regional or distant). Panel (A) indicates Kaplan&#x02013;Meier curves for cancer stage: In&#x000a0;situ or localized. Panel (B) indicates Kaplan&#x02013;Meier curves for cancer stage: Regional or distant. We used a multivariable Cox proportional hazard model to compare the impact of ICD with Amiodarone on long&#x02010;term all&#x02010;cause mortality (5&#x02009;years). Multivariable model: Adjusted for age, gender, diabetes, chronic kidney disease, prior myocardial infarction, chronic heart failure, VT/VF, interval from diagnosis of cancer to treatment. CI, confidence interval; HR, hazard ratio; ICD, Implantable cardioverter&#x02010;defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia.</p></caption><graphic xlink:href="JOA3-41-e70093-g002" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="joa370093-sec-0014"><label>3.3</label><title>Sensitivity analysis</title><p>Propensity score matching identified 92 patients between the ICD group and the Amiodarone group (46 patients each) (Table&#x000a0;<xref rid="joa370093-tbl-0002" ref-type="table">2</xref>). Baseline characteristics were generally well balanced and were largely comparable between the two groups (Table&#x000a0;<xref rid="joa370093-tbl-0002" ref-type="table">2</xref>). Kaplan&#x02013;Meier analysis and univariable Cox proportional hazard model demonstrated significantly better 5&#x02010;year all&#x02010;cause outcomes in the ICD group compared to the Amiodarone group (Log&#x02010;rank test, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.009; Hazard ratio: 0.46, 95% confidence interval: 0.26&#x02013;0.81, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.008) (Figure&#x000a0;<xref rid="joa370093-fig-0004" ref-type="fig">4</xref>).</p><table-wrap position="float" id="joa370093-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Baseline characteristics after propensity score matching.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Amiodarone</th><th align="left" valign="bottom" rowspan="1" colspan="1">ICD</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="left" valign="bottom" rowspan="1" colspan="1">SMD</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Number</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient data</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age, (years)</td><td align="left" valign="top" rowspan="1" colspan="1">70 [65, 78]</td><td align="left" valign="top" rowspan="1" colspan="1">73 [67, 76]</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.907</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.083</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (23.9)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (17.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.606</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.162</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabetes, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (32.6)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (43.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.225</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic kidney disease, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (17.4)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (23.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.606</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.162</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prior myocardial infarction</td><td align="left" valign="top" rowspan="1" colspan="1">9 (19.6)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (21.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cardiomyopathy, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (26.1)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (23.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic heart failure, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (76.1)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (73.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NYHA II or more, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (23.9)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (37.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.257</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.286</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">History of VT or VF, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (52.2)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (52.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancer</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Interval between cancer diagnosis and treatment (days)</td><td align="left" valign="top" rowspan="1" colspan="1">487 [66, 1058]</td><td align="left" valign="top" rowspan="1" colspan="1">530 [273, 921]</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.517</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.096</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cancer stage: in&#x000a0;situ or localized, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (54.3)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (58.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.833</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.088</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cancer stage: regional, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (30.4)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (21.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.476</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cancer stage: distant, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Stomach, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (17.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.199</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Colon, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (26.1)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (21.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.807</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.102</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lung, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (10.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.711</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.155</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liver, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003e;.999</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.211</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medications</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ACE or ARB, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (71.7)</td><td align="left" valign="top" rowspan="1" colspan="1">38 (82.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.32</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.261</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MRA, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (58.7)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (73.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.186</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.326</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x003b2;&#x02010;blocker, (%)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (78.3)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (89.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">.259</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.297</td></tr></tbody></table><table-wrap-foot id="joa370093-ntgp-0002"><fn id="joa370093-note-0003"><p>
<italic toggle="yes">Note</italic>: Data are expressed as median [interquartile range] or number (column percentage).</p></fn><fn id="joa370093-note-0004"><p>Abbreviations: SMD, standardized mean difference; others are the same as Table&#x000a0;<xref rid="joa370093-tbl-0001" ref-type="table">1</xref>.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="joa370093-fig-0004"><label>FIGURE 4</label><caption><p>Kaplan&#x02013;Meier curves after propensity score matching. Propensity score was estimated for each patient by logistic regression using the following parameters: age, gender, cancer stage: In&#x000a0;situ or localized, cancer stage: Regional, cancer stage: Distant, interval from diagnosis of cancer to treatment, cardiomyopathy, VT/VF. Based on the propensity score, 1:1 matching was performed between patients with Amiodarone and ICD. We used a univariable Cox proportional hazard model to compare the impact of ICD with Amiodarone on long&#x02010;term all&#x02010;cause mortality (5&#x02009;years). CI, confidence interval; HR, hazard ratio; ICD, Implantable cardioverter&#x02010;defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia.</p></caption><graphic xlink:href="JOA3-41-e70093-g001" position="anchor" id="jats-graphic-9"/></fig></sec></sec><sec sec-type="discussion" id="joa370093-sec-0015"><label>4</label><title>DISCUSSION</title><p>The present study from cancer registry linked with administrative data demonstrated the following findings: (1) cancer patients with ICDs had a better long&#x02010;term outcome than those with amiodarone, and ICD was an independent prognostic factor among this population; (2) in patients with cancer stage: in&#x000a0;situ or localized, ICDs showed no significant association with long&#x02010;term outcome; and (3) in patients with cancer stage: regional or distant, ICD was an independent prognostic factor.</p><p>In cancer patients, relative benefit of ICD therapy might be limited because of competing risk of nonarrhythmic mortality such as cancer death. Research on ICD therapy limited to cancer patients might be difficult because of sample size, so there is no information on comparing the long&#x02010;term prognosis between patients with ICD and amiodarone in cancer patients. However, using large&#x02010;scale cancer registry linked with administrative data, our study is the first to demonstrate that in cancer patients, ICD therapy might improve long&#x02010;term outcome compared to amiodarone. Enriquez et&#x000a0;al. retrospectively analyzed 1598 patients who received an ICD implantation at two facilities in Ontario, Canada, between 2007 and 2015. Of these, 209 (13.1%) were diagnosed with cancer, and the occurrence of ventricular arrhythmia was significantly higher than in patients without cancer.<xref rid="joa370093-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> In a cohort study for patients with a first&#x02010;time ICD implantation (<italic toggle="yes">N</italic>&#x02009;=&#x02009;5665) using Danish nationwide registry from 2007 to 2012, out of these [289 (5.1%)] were diagnosed with cancer, and cancer was associated with elevated mortality in patients with ICD for secondary prevention, whereas no such association was observed in those for primary prevention.<xref rid="joa370093-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Since both studies were conducted on patients with pre&#x02010;implanted ICD, the ability to comprehensively assess the efficacy of ICD in cancer patients remains limited. On the other hand, in a single&#x02010;center retrospective cohort study for patients with cancer who were eligible for primary ICD therapy, there was no statistically significant difference in survival rates between cancer patients with and without ICD (hazard ratio 0.521, <italic toggle="yes">p</italic>&#x02009;=&#x02009;.127).<xref rid="joa370093-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> However, this study was constrained by a limited sample size (<italic toggle="yes">N</italic>&#x02009;=&#x02009;75), and the impact of antiarrhythmic drugs such as amiodarone, was not assessed.</p><p>The strength of our study stems from using a large&#x02010;scale cancer registry linked with administrative data, which enabled us to identify patients who received a new ICD implantation or were newly prescribed amiodarone after a cancer diagnosis. Among cancer patients, ICD showed a significant impact on improving prognosis compared to amiodarone. This result was also consistent in the sensitivity analysis using propensity score matching. Notably, among patients with cancer stage: in&#x000a0;situ or localized, ICD demonstrated no significant advantage in prognosis compared to amiodarone; nevertheless, among patients with a more advanced cancer stage: regional or distant, ICD was associated with a significant improvement in prognosis compared to amiodarone. As elaborated upon subsequently, the progression of cancer may elevate the risk of ventricular arrhythmias. With the global rise in cancer prevalence and improved long&#x02010;term survival rates,<xref rid="joa370093-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="joa370093-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="joa370093-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> healthcare providers are increasingly encountering complex clinical scenarios, such as choosing between ICD or amiodarone for cancer patients, necessitating more nuanced decision&#x02010;making in this situation. However, any guidelines have no mention of the relationship between ICD implantation and cancer and recommend a minimum estimated survival of 1&#x02009;year.<xref rid="joa370093-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="joa370093-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="joa370093-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Only 27% of patients eligible for a primary prevention ICD, as per guideline recommendations, ultimately received the device.<xref rid="joa370093-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Therefore, it is crucial to assess the suitability of ICD implantation within this population, and our findings may provide valuable insights toward this problem, though further research is needed to optimize their application in the oncologic setting.</p><sec id="joa370093-sec-0016"><label>4.1</label><title>Heart disease in cancer patients</title><p>In a cohort study that used data from the same registry, cancer patients had a higher risk of cardiac death than general patients, and the standardized mortality ratio for heart disease was 2.80 (95% CI, 2.74&#x02013;2.85), and the risk of heart&#x02010;related death showed a progressive increase over time following a cancer diagnosis.<xref rid="joa370093-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Inflammation enhances all stages of carcinogenesis, and Neuroendocrine factors, oxidative stress, pro&#x02010;inflammatory cytokines, and dysregulation of the immune system have been identified as contributors to the heightened risk of cardiovascular disease in oncology patients.<xref rid="joa370093-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="joa370093-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Certain anticancer agents, such as anthracyclines,<xref rid="joa370093-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> tyrosine kinase inhibitors,<xref rid="joa370093-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and immune checkpoint inhibitors,<xref rid="joa370093-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="joa370093-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> are associated with cardiotoxicity as an adverse side effect. Numerous other anticancer agents have been documented to possess the potential to induce arrhythmias.<xref rid="joa370093-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Moreover, an increased risk of cardiovascular complications linked to surgical interventions and radiotherapy has also been reported.<xref rid="joa370093-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="joa370093-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Therefore, cancer patients are generally considered a population at an increased risk for adverse cardiac events. In our cohort, chronic heart failure was prevalent in 59.3% of patients (201 out of 339), indicating that this group of cancer patients faced an exceptionally increased risk of adverse cardiac events, including VT/VF. Nonsustained VT and frequent premature ventricular contractions in 24&#x02010;h electrocardiogram recording were factors that worsened the long&#x02010;term prognosis among cancer patients.<xref rid="joa370093-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="joa370093-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> From the above, understanding the intricate relationship between cancer therapies and arrhythmogenesis is crucial for devising targeted interventions, such as ICD or amiodarone, aimed at mitigating the prevalence of arrhythmic events in this population.</p></sec><sec id="joa370093-sec-0017"><label>4.2</label><title>Cancer progression and ventricular arrhythmias</title><p>In our study, among patients with cancer stage: in&#x000a0;situ or localized, ICD demonstrated no significant advantage in prognosis compared to amiodarone. On the other hand, among patients with more advanced cancer stage: regional or distant, ICD was associated with a significant improvement in prognosis compared to amiodarone. In a previous study for cancer patients with ICD, patients with stage 4 had a significantly more frequent incidence of VT/VF than those with other stages.<xref rid="joa370093-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Curative treatment is typically the primary strategy for early&#x02010;stage cancer, often supplemented by adjuvant chemotherapy. On the other hand, in advanced cancer, molecular&#x02010;targeted therapies and immune checkpoint inhibitors frequently constitute the cornerstone of treatment alongside conventional anticancer agents. However, it is well established that these anticancer drugs exhibit a proarrhythmic effect, including prolongation of the QT interval.<xref rid="joa370093-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> The risk of heart&#x02010;related death showed a progressive increase over time following a cancer diagnosis.<xref rid="joa370093-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Therefore, it is evident that patients with advanced stages of cancer face a heightened risk of fatal arrhythmias, suggesting a potential increase in the effectiveness of ICD within this population. Considering the improvement in the long&#x02010;term prognosis for cancer patients,<xref rid="joa370093-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="joa370093-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> it may be essential to conduct individualized assessments of prognosis, even for those with advanced stages of cancer, and to make decisions from multiple perspectives.</p></sec><sec id="joa370093-sec-0018"><label>4.3</label><title>Limitations</title><p>Our study has several limitations. First, the dosage of amiodarone administered could not be identified because of the unavailability of information from the linked dataset. The dosage of amiodarone can significantly influence the suppression of VT/VF, representing a major limitation. Second, though the ICD group included 65.5% who underwent CRT&#x02010;D, we could not evaluate the impact of CRT&#x02010;D through biventricular pacing on improving outcomes. Third, despite performing multivariable analyses and propensity score matching, the potential for residual selection bias in the allocation of ICD or amiodarone might not be entirely eliminated. Fourth, because of the unavailability of blood and echocardiographic data, we were unable to include these parameters in our evaluation. Fifth, the specific cause of death, such as cancer or cardiovascular disease, could not be identified from our dataset. Finally, amiodarone exerts a QT interval&#x02010;prolonging effect, and it cannot be ruled out that this property may have contributed to an increased risk of proarrhythmic events in cancer patients.</p></sec></sec><sec sec-type="conclusions" id="joa370093-sec-0019"><label>5</label><title>CONCLUSIONS</title><p>In cancer patients, ICD may improve long&#x02010;term prognosis compared to amiodarone, especially in patients with advanced cancer stages.</p></sec><sec id="joa370093-sec-0020"><title>AUTHOR CONTRIBUTIONS</title><p>I.M. contributed to the acquisition of data. T.M. contributed to the curation and interpretation of data. All authors revised the manuscript critically and approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></sec><sec sec-type="COI-statement" id="joa370093-sec-0023"><title>CONFLICT OF INTEREST STATEMENT</title><p>There is no conflict of interest to declare.</p></sec><sec id="joa370093-sec-0024"><title>ETHICS APPROVAL STATEMENT</title><p>This study was approved by the local ethics committee of Osaka International Cancer Institute, which approved the study protocol (Approval number: 1707105108). Informed consent was not required, as the study was retrospective in nature, and the committee allowed for the opt&#x02010;out approach for the secondary use of existing data.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="joa370093-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="JOA3-41-e70093-s001.docx"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="joa370093-sec-0022"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available on reasonable request from the corresponding author. The data are not publicly available because of privacy and ethical restrictions.</p></sec><ref-list content-type="cited-references" id="joa370093-bibl-0001"><title>REFERENCES</title><ref id="joa370093-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="joa370093-cit-0001">
<collab collab-type="authors">Collaborators GCoD</collab>
. <article-title>Global, regional, and national age&#x02010;sex specific mortality for 264 causes of death, 1980&#x02010;2016: a systematic analysis for the global burden of disease study 2016</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>390</volume>(<issue>10100</issue>):<fpage>1151</fpage>&#x02013;<lpage>1210</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32152-9</pub-id>
<pub-id pub-id-type="pmid">28919116</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="joa370093-cit-0002">
<string-name>
<surname>Sung</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Siegel</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Laversanne</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Soerjomataram</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Jemal</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. <year>2021</year>;<volume>71</volume>(<issue>3</issue>):<fpage>209</fpage>&#x02013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="joa370093-cit-0003">
<string-name>
<surname>Matsuda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ajiki</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Marugame</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ioka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tsukuma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sobue</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Population&#x02010;based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study</article-title>. <source>Jpn J Clin Oncol</source>. <year>2011</year>;<volume>41</volume>(<issue>1</issue>):<fpage>40</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyq167</pub-id>
<pub-id pub-id-type="pmid">20819833</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="joa370093-cit-0004">
<string-name>
<surname>Allemani</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Weir</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Carreira</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Harewood</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Spika</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>XS</given-names>
</string-name>, et&#x000a0;al. <article-title>Global surveillance of cancer survival 1995&#x02013;2009: analysis of individual data for 25,676,887 patients from 279 population&#x02010;based registries in 67 countries (CONCORD&#x02010;2)</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>385</volume>(<issue>9972</issue>):<fpage>977</fpage>&#x02013;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)62038-9</pub-id>
<pub-id pub-id-type="pmid">25467588</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="joa370093-cit-0005">
<string-name>
<surname>De Angelis</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coleman</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Francisci</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baili</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pierannunzio</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Cancer survival in Europe 1999&#x02013;2007 by country and age: results of EUROCARE&#x02010;&#x02010;5&#x02010;a population&#x02010;based study</article-title>. <source>Lancet Oncol</source>. <year>2014</year>;<volume>15</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(13)70546-1</pub-id>
<pub-id pub-id-type="pmid">24314615</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="joa370093-cit-0006">
<string-name>
<surname>de Boer</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Meijers</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>van der Meer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>van Veldhuisen</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Cancer and heart disease: associations and relations</article-title>. <source>Eur J Heart Fail</source>. <year>2019</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1515</fpage>&#x02013;<lpage>1525</lpage>. <pub-id pub-id-type="doi">10.1002/ejhf.1539</pub-id>
<pub-id pub-id-type="pmid">31321851</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="joa370093-cit-0007">
<string-name>
<surname>Gon</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zha</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mochizuki</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Heart disease mortality in cancer survivors: a population&#x02010;based study in Japan</article-title>. <source>J Am Heart Assoc</source>. <year>2023</year>;<volume>12</volume>(<issue>23</issue>):<elocation-id>e029967</elocation-id>. <pub-id pub-id-type="doi">10.1161/JAHA.123.029967</pub-id>
<pub-id pub-id-type="pmid">38014664</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="joa370093-cit-0008">
<string-name>
<surname>Moss</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Zareba</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wilber</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Cannom</surname>
<given-names>DS</given-names>
</string-name>, et&#x000a0;al. <article-title>Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>346</volume>(<issue>12</issue>):<fpage>877</fpage>&#x02013;<lpage>883</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa013474</pub-id>
<pub-id pub-id-type="pmid">11907286</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="joa370093-cit-0009">
<string-name>
<surname>Zeppenfeld</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tfelt&#x02010;Hansen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>de Riva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Winkel</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Behr</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Blom</surname>
<given-names>NA</given-names>
</string-name>, et&#x000a0;al. <article-title>2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death</article-title>. <source>Eur Heart J</source>. <year>2022</year>;<volume>43</volume>(<issue>40</issue>):<fpage>3997</fpage>&#x02013;<lpage>4126</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehac262</pub-id>
<pub-id pub-id-type="pmid">36017572</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="joa370093-cit-0010">
<string-name>
<surname>Bardy</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Mark</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Poole</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Packer</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Boineau</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Amiodarone or an implantable cardioverter&#x02010;defibrillator for congestive heart failure</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>3</issue>):<fpage>225</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa043399</pub-id>
<pub-id pub-id-type="pmid">15659722</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="joa370093-cit-0011">
<string-name>
<surname>Christensen</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Bjerre</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jons</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vinther</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gislason</surname>
<given-names>GH</given-names>
</string-name>, et&#x000a0;al. <article-title>Clinical outcome in patients with implantable cardioverter&#x02010;defibrillator and cancer: a nationwide study</article-title>. <source>Europace</source>. <year>2019</year>;<volume>21</volume>(<issue>3</issue>):<fpage>465</fpage>&#x02013;<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1093/europace/euy268</pub-id>
<pub-id pub-id-type="pmid">30535192</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="joa370093-cit-0012">
<string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kuwabara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Odani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kudo</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Patterns of staging, treatment, and mortality in gastric, colorectal, and lung cancer among older adults with and without preexisting dementia: a Japanese multicentre cohort study</article-title>. <source>BMC Cancer</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>67</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-022-10411-y</pub-id>
<pub-id pub-id-type="pmid">36658524</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="joa370093-cit-0013">
<string-name>
<surname>Kuwabara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kudo</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Koyama</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Prognostic impact of coexisting cardiovascular disease in patients with cancer: a multicenter retrospective cohort study</article-title>. <source>Heliyon</source>. <year>2024</year>;<volume>10</volume>(<issue>3</issue>):<elocation-id>e25594</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e25594</pub-id>
<pub-id pub-id-type="pmid">38356609</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="joa370093-cit-0014">
<string-name>
<surname>Gon</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kawano</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Okazaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Todo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Arterial thromboembolism in Japanese patients with cancer: incidence, predictors, and survival impact</article-title>. <source>JACC CardioOncol</source>. <year>2024</year>;<volume>6</volume>(<issue>2</issue>):<fpage>283</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaccao.2024.01.006</pub-id>
<pub-id pub-id-type="pmid">38774004</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="joa370093-cit-0015">
<string-name>
<surname>Kida</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tsubakihara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Miyashiro</surname>
<given-names>I</given-names>
</string-name>. <article-title>Stage at diagnosis and prognosis of colorectal, stomach, lung, liver, kidney, and bladder cancers in dialysis patients: a multicenter retrospective study using cancer registry data and administrative data</article-title>. <source>Nephron</source>. <year>2022</year>;<volume>146</volume>(<issue>5</issue>):<fpage>429</fpage>&#x02013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1159/000521603</pub-id>
<pub-id pub-id-type="pmid">35093954</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0016"><label>16</label><mixed-citation publication-type="book" id="joa370093-cit-0016">
<collab collab-type="authors">National Cancer Institute (U.S.). Cancer Statistics Branch., Young JL, SEER Program (National Cancer Institute (U.S.))</collab>
. <source>SEER summary staging manual 2000: codes and coding instructions</source>. <publisher-loc>National Cancer Institute, National Institutes of Health</publisher-loc>: <publisher-name>NIH Publication</publisher-name>; <year>2001</year>.</mixed-citation></ref><ref id="joa370093-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="joa370093-cit-0017">
<string-name>
<surname>Hamada</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sekimoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Imanaka</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Effects of the per diem prospective payment system with DRG&#x02010;like grouping system (DPC/PDPS) on resource usage and healthcare quality in Japan</article-title>. <source>Health Policy</source>. <year>2012</year>;<volume>107</volume>(<issue>2&#x02013;3</issue>):<fpage>194</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.healthpol.2012.01.002</pub-id>
<pub-id pub-id-type="pmid">22277879</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="joa370093-cit-0018">
<string-name>
<surname>Quan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sundararajan</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Halfon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Fong</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Burnand</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Luthi</surname>
<given-names>JC</given-names>
</string-name>, et&#x000a0;al. <article-title>Coding algorithms for defining comorbidities in ICD&#x02010;9&#x02010;CM and ICD&#x02010;10 administrative data</article-title>. <source>Med Care</source>. <year>2005</year>;<volume>43</volume>(<issue>11</issue>):<fpage>1130</fpage>&#x02013;<lpage>1139</lpage>. <pub-id pub-id-type="doi">10.1097/01.mlr.0000182534.19832.83</pub-id>
<pub-id pub-id-type="pmid">16224307</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="joa370093-cit-0019">
<string-name>
<surname>Nagai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inomata</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kohno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tada</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kubo</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>JCS 2023 guideline on the diagnosis and treatment of myocarditis</article-title>. <source>Circ J</source>. <year>2023</year>;<volume>87</volume>(<issue>5</issue>):<fpage>674</fpage>&#x02013;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-22-0696</pub-id>
<pub-id pub-id-type="pmid">36908170</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="joa370093-cit-0020">
<string-name>
<surname>Takase</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Aiba</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chinushi</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>JCS/JHRS 2022 guideline on diagnosis and risk assessment of arrhythmia</article-title>. <source>Circ J</source>. <year>2024</year>;<volume>88</volume>(<issue>9</issue>):<fpage>1509</fpage>&#x02013;<lpage>1595</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-22-0827</pub-id>
<pub-id pub-id-type="pmid">37690816</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="joa370093-cit-0021">
<string-name>
<surname>Enriquez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Biagi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Redfearn</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Boles</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kamel</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>FS</given-names>
</string-name>, et&#x000a0;al. <article-title>Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter&#x02010;defibrillators</article-title>. <source>JACC Clin Electrophysiol</source>. <year>2017</year>;<volume>3</volume>(<issue>1</issue>):<fpage>50</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacep.2016.03.001</pub-id>
<pub-id pub-id-type="pmid">29759695</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="joa370093-cit-0022">
<string-name>
<surname>Itzhaki Ben Zadok</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Agmon</surname>
<given-names>N</given-names>
<suffix>I</suffix>
</string-name>, <string-name>
<surname>Neiman</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Abdel&#x02010;Latif</surname>
<given-names>A</given-names>
</string-name>. <article-title>Implantable cardioverter defibrillator for the primary prevention of sudden cardiac death among patients with cancer</article-title>. <source>Am J Cardiol</source>. <year>2023</year>;<volume>191</volume>:<fpage>32</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2022.12.013</pub-id>
<pub-id pub-id-type="pmid">36634547</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="joa370093-cit-0023">
<string-name>
<surname>Al&#x02010;Khatib</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Callans</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>AB</given-names>
</string-name>, et&#x000a0;al. <article-title>AHA/ACC/HRS guideline for Management of Patients with Ventricular Arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>138</volume>(<issue>13</issue>):<fpage>e210</fpage>&#x02013;<lpage>e271</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000548</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="joa370093-cit-0024">
<string-name>
<surname>Meijers</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>de Boer</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Common risk factors for heart failure and cancer</article-title>. <source>Cardiovasc Res</source>. <year>2019</year>;<volume>115</volume>(<issue>5</issue>):<fpage>844</fpage>&#x02013;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvz035</pub-id>
<pub-id pub-id-type="pmid">30715247</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="joa370093-cit-0025">
<string-name>
<surname>Guglin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aljayeh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Saiyad</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>AB</given-names>
</string-name>. <article-title>Introducing a new entity: chemotherapy&#x02010;induced arrhythmia</article-title>. <source>Europace</source>. <year>2009</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1579</fpage>&#x02013;<lpage>1586</lpage>. <pub-id pub-id-type="doi">10.1093/europace/eup300</pub-id>
<pub-id pub-id-type="pmid">19801562</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="joa370093-cit-0026">
<string-name>
<surname>Lenihan</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Kowey</surname>
<given-names>PR</given-names>
</string-name>. <article-title>Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors</article-title>. <source>Oncologist</source>. <year>2013</year>;<volume>18</volume>(<issue>8</issue>):<fpage>900</fpage>&#x02013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2012-0466</pub-id>
<pub-id pub-id-type="pmid">23918069</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="joa370093-cit-0027">
<string-name>
<surname>Lyon</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Yousaf</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Battisti</surname>
<given-names>NML</given-names>
</string-name>, <string-name>
<surname>Moslehi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Larkin</surname>
<given-names>J</given-names>
</string-name>. <article-title>Immune checkpoint inhibitors and cardiovascular toxicity</article-title>. <source>Lancet Oncol</source>. <year>2018</year>;<volume>19</volume>(<issue>9</issue>):<fpage>e447</fpage>&#x02013;<lpage>e458</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30457-1</pub-id>
<pub-id pub-id-type="pmid">30191849</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="joa370093-cit-0028">
<string-name>
<surname>Ball</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Wongsaengsak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bandyopadhyay</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Aronow</surname>
<given-names>WS</given-names>
</string-name>, et&#x000a0;al. <article-title>Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week</article-title>. <source>J Am Coll Cardiol</source>. <year>2019</year>;<volume>74</volume>(<issue>13</issue>):<fpage>1714</fpage>&#x02013;<lpage>1727</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2019.07.079</pub-id>
<pub-id pub-id-type="pmid">31558256</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="joa370093-cit-0029">
<string-name>
<surname>Herrmann</surname>
<given-names>J</given-names>
</string-name>. <article-title>Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia</article-title>. <source>Nat Rev Cardiol</source>. <year>2020</year>;<volume>17</volume>(<issue>8</issue>):<fpage>474</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-020-0348-1</pub-id>
<pub-id pub-id-type="pmid">32231332</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="joa370093-cit-0030">
<string-name>
<surname>Smilowitz</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ramakrishna</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Bangalore</surname>
<given-names>S</given-names>
</string-name>. <article-title>Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery</article-title>. <source>JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>(<issue>2</issue>):<fpage>181</fpage>&#x02013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1001/jamacardio.2016.4792</pub-id>
<pub-id pub-id-type="pmid">28030663</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="joa370093-cit-0031">
<string-name>
<surname>Belzile&#x02010;Dugas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Eisenberg</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Radiation&#x02010;induced cardiovascular disease: review of an Underrecognized pathology</article-title>. <source>J Am Heart Assoc</source>. <year>2021</year>;<volume>10</volume>(<issue>18</issue>):<elocation-id>e021686</elocation-id>. <pub-id pub-id-type="doi">10.1161/JAHA.121.021686</pub-id>
<pub-id pub-id-type="pmid">34482706</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="joa370093-cit-0032">
<string-name>
<surname>Albrecht</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Porthun</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eucker</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Coats</surname>
<given-names>AJS</given-names>
</string-name>, <string-name>
<surname>von Haehling</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pezzutto</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Spontaneous non&#x02010;sustained ventricular tachycardia and premature ventricular contractions and their prognostic relevance in patients with cancer in routine care</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>(<issue>10</issue>):2303. <pub-id pub-id-type="doi">10.3390/cancers13102303</pub-id>
</mixed-citation></ref><ref id="joa370093-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="joa370093-cit-0033">
<string-name>
<surname>Anker</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>von Haehling</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Coats</surname>
<given-names>AJS</given-names>
</string-name>, <string-name>
<surname>Riess</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Eucker</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Porthun</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study</article-title>. <source>Eur J Heart Fail</source>. <year>2021</year>;<volume>23</volume>(<issue>1</issue>):<fpage>145</fpage>&#x02013;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1002/ejhf.2059</pub-id>
<pub-id pub-id-type="pmid">33222388</pub-id>
</mixed-citation></ref></ref-list></back></article>